Oddity Tech Ltd.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Operating globally, Oddity Tech Ltd. and its affiliated companies function as a consumer technology enterprise. It delivers beauty and wellness merchandise, leveraging its proprietary PowerMatch techn...
Latest News
4 days ago · zacks.com
New Strong Buy Stocks for October 29thODD, BOOM, BSRR, AIN and MUR have been added to the Zacks Rank #1 (Strong Buy) List on October 29th, 2026.
5 days ago · globenewswire.com
ODDITY to Announce Third Quarter 2026 Financial Results on November 11, 2026NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its third quarter 2026 financial results before the market open on Wednesday, November 11, 2026, to be followed by a conference call at 8:30 a.m. Eastern Time.
6 days ago · gurufocus.com
Baillie Gifford Trims ODDITY Tech Ltd (ODD) Stake -- Shares Look 55% Undervalued on GF ValueA Small Trim Within a Long-Term Framework Baillie Gifford (Trades, Portfolio) reduced its position in ODDITY Tech Ltd (ODD) on 2026-09-30, selling 398,467 share
11 days ago · gurufocus.com
ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology and Phase 2 Clinical Pipelines at BIO-Europe 2026PR NewswireSEOUL, South Ko
12 days ago · gurufocus.com
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027- Resubmission includes Chemistry, Manufacturing, and Controls (CMC) data from new drug product (DP) manufacturing vendorMountain View, CA, Oct 22, 2026 - (ACN
18 days ago · zacks.com
Oddity Tech (ODD) Upgraded to Strong Buy: Here's What You Should KnowOddity Tech (ODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
1 month ago · globenewswire.com
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory RecognitionNANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company's proprietary PD‑L1/4‑1BB bispecific antibody, has been granted Orphan Drug Designation (ODD) by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is the third Orphan Drug Designation for opamtistomig, following designations in the U.S. Food and Drug Administration (FDA) and the European Commission (EC), marking a further expansion of its global regulatory recognition into a strategically important Asian market.
1 month ago · gurufocus.com
ODDITY Tech Ltd (ODD) Shares Fall 5.1% -- What GF Score of 71 Tells InvestorsOn September 23, 2026, ODDITY Tech Ltd (ODD) shares fell 5.1% to $17.83, reflecting a significant drop in price performance over the last year, with a 52-week r
2 months ago · zacks.com
Earnings Estimates Moving Higher for Oddity Tech (ODD): Time to Buy?Oddity Tech (ODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
8 months ago · businesswire.com
Oddity Tech Ltd. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – ODDLOS ANGELES--(BUSINESS WIRE)--Oddity Tech Ltd. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – ODD.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ODD